V domain of RAGE interacts with AGEs on prostate carcinoma cells

Prostate

Volumn 68, Issue 7, 2008, Pages 748-758

  Uetz Von Allmen, Edith ^a   Koch, Michael ^b   Fritz, Günter ^b   Legler, Daniel F ^a  

^a UNIVERSITY OF KONSTANZ   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Advanced glycation end products; Prostate carcinoma; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMPHOTERICIN; ANDROGEN; BETA INTEGRIN; LIGAND; NEUTRALIZING ANTIBODY; PROTEIN S100B;

ARTICLE; BINDING KINETICS; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL ADHESION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMOBILIZATION; INHIBITION KINETICS; MALE; MOLECULAR INTERACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN INTERACTION;

EID: 43049127240     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20736     Document Type: Article

References (29)

1. 1 Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992 ; 267 (21): 14998–15004.
2. 2 Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998 ; 4 (9): 1025–1031.
3. 3 Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid‐beta peptide neurotoxicity in Alzheimer's disease. Nature 1996 ; 382 (6593): 685–691.
4. 4 Chavakis T, Bierhaus A, Al‐Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003 ; 198 (10): 1507–1515.
5. 5 Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE‐amphoterin signalling suppresses tumour growth and metastases. Nature 2000 ; 405 (6784): 354–360.
6. 6 Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 ; 97 (7): 889–901.
7. 7 Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, Huber G. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co‐expressing cell‐surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999 ; 71 (2): 159–170.
8. 8 Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end‐products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes‐induced vascular injury. Biochem J 2003 ; 370 (Pt 3): 1097–1109.
9. 9 Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005 ; 25 (12): 2587–2593.
10. 10 Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006 ; 55 (9): 1227–1231.
11. 11 Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 2007 ; 27 (6): e32 ; author reply e33–e34.
12. 12 Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D. Calcium‐binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005 ; 11 (14): 5146–5152.
13. 13 Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003 ; 10 (6): 1863–1868.
14. 14 Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005 ; 64 (1): 92–100.
15. 15 Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP. Diabetes‐associated sustained activation of the transcription factor nuclear factor‐kappaB. Diabetes 2001 ; 50 (12): 2792–2808.
16. 16 Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM, Hughes TE. Advanced glycation end product ligands for the receptor for advanced glycation end products: Biochemical characterization and formation kinetics. Anal Biochem 2004 ; 324 (1): 68–78.
17. 17 Westwood ME, Thornalley PJ. Molecular characteristics of methylglyoxal‐modified bovine and human serum albumins. Comparison with glucose‐derived advanced glycation endproduct‐modified serum albumins. J Protein Chem 1995 ; 14 (5): 359–372.
18. 18 Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 2007 ; 46 (23): 6957–6970.
19. 19 Ostendorp T, Heizmann CW, Kroneck PM, Fritz G. Purification, crystallization and preliminary X‐ray diffraction studies on human Ca2+‐binding protein S100B. Acta Crystallograph Sect F Struct Biol Cryst Commun 2005 ; 61 (Pt 7): 673–675.
20. 20 Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symons M. Cell migration and invasion assays. Methods 2005 ; 37 (2): 208–215.
21. 21 Legler DF, Johnson‐Leger C, Wiedle G, Bron C, Imhof BA. The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes. Eur J Immunol 2004 ; 34 (6): 1608–1616.
22. 22 Legler DF, Wiedle G, Ross FP, Imhof BA. Superactivation of integrin alpha v beta 3 by low antagonist concentrations. J Cell Sci 2001 ; 114 (Pt 8): 1545–1553.
23. 23 Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B, Heizmann CW, Kroneck PM, Fritz G. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 2007 ; 26 (16): 3868–3878.
24. 24 Osawa M, Yamamoto Y, Munesue S, Murakami N, Sakurai S, Watanabe T, Yonekura H, Uchigata Y, Iwamoto Y, Yamamoto H. De‐N‐glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim Biophys Acta 2007 ; 1770 (10): 1468–1474.
25. 25 Wilton R, Yousef MA, Saxena P, Szpunar M, Stevens FJ. Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli. Protein Expr Purif 2006 ; 47 (1): 25–35.
26. 26 Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface‐binding proteins for advanced glycation end products. J Clin Invest 1993 ; 91 (5): 2155–2168.
27. 27 Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004 ; 164 (3): 441–449.
28. 28 Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM. N(epsilon)‐(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999 ; 274 (44): 31740–31749.
29. 29 Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, Chang J, Brown WR, Cantarero LA. The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods 1992 ; 150 (1–2): 77–90.